13:30 – 14:00 Opening/ Registration
Breast and Gynecological Session
14:00 – 14:20 TNBC Early stage | Dr. Mircea Dediu
14:20 – 14:40 TNBC Advanced disease | Conf. Dr. Laurenția Galeș
14:40 – 15:00 ER/PR Positive (Early/Advanced) | Prof. Dr. Rupert Bartsch
15:00 – 15:20 Her2 Positive (Early/Advanced) | Prof. Dr. Rupert Bartsch
15:20 – 15:40 Ovarian Carcinoma | Prof. Dr. Christoph Grimm
15:40 – 16:00 Endometrial Carcinoma | Prof. Dr. Christoph Grimm
16:00 – 16:40 Satellite Symposium AstraZeneca – Evidence to Practice: Management of HER2-Low and HER2+ mBC with ENHERTU | Dr. Isabela Anda Komporaly, Dr. Vladimir Preoteasa
16:40 – 17:00 Coffee Break
17:00 – 17:30 Satellite Symposium Eli Lilly – From eBC to mBC: the role and efficacy of Verzenios in HR+ HER2- breast cancer | Conf. Dr. Laurenția Galeș, Conf. Dr. Oana Trifănescu
17:30 – 17:50 Satellite Symposium AstraZeneca – Changing perspective in endometrial cancer: A new partnership between immunotherapy and targeted therapy | Dr. Raluca Mihăilă
17:50 – 18:10 Symposia AstraZeneca – Cancer genito-urinar – Significant milestones in the treatment of mCRPC | Dr. Vladimir Preoteasa
Varia Session
18:10 – 18:30 CNS Tumors | Conf. Dr. Radu Mitrica
18:30 – 18:50 Sarcoma | Prof. Dr. Thomas Brodowicz
18:50 – 19:10 Radiotherapy for adult sarcomas | Prof. Dr. Gabriel Kacso
19:10 – 19:30 Updates in Melanoma | Prof. Dr. Christoph Hoeller
19:30 – 19:50 EU Projects – Dr. Laser & others | Prof. Dr. Anghel Rodica
19:50 – 20:10 AI in Oncology | Conf. Univ. Dr. Liviu Bîlteanu
20:10 – 20:30 Heavy Ions | Prof. Dr. Piero Fossati
Urogenital
14:00 – 14:20 Treatment options for non-muscle invasive bladder cancer | Conf. Dr. Laurenția Galeș
14:20 – 14:40 The biochemical PSA relapse: definition and current approach | Conf. Dr. Anca Zgură
14:40 – 15:00 The ADC in the treatment landscape of BC | Prof. Dr. Lucian Miron
15:00 – 15:20 Conservative approach of MIBC – (Muscle invasive) | Univ. Prof. Priv. Dr. Mesut REMZI
15:20 – 15:40 Adjuvant treatment in RCC | Prof. Dr. Șerban Negru
15:40 – 16:00 First line treatment in mRCC | Prof. Dr. Manuela Schmidinger
16:00 – 16:30 Satellite Symposium Merck – Avelumab maintenance in advanced urothelial carcinoma: From evidence to clinical practice | Conf. Dr. Laurenția Galeș, Dr. Elena Șerban
16:30 – 17:00 Satellite Symposium Ipsen – RCC management: multidisciplinary decisions in clinical practice | Dr. Andreea Lăzescu, Dr. Cristian Mirvald
17:00 – 17:20 Satellite Symposium Astellas – The Importance of Early Intensification and 1st Treatment Choice in mHSPC | Conf. Dr. Oana Trifănescu
17:20 – 17:40 Coffee Break
17:40 – 18:00 Satellite Symposium AstraZeneca – IMFINZI: A Journey throughout NSCLC & SCLC | Conf. Dr. Laurenția Galeș
Pulmonar
18:00 – 18:50 Debate: Potentially resectable NSCLC: how to address?
18:00 – 18:20 In favour of neoadjuvant ICI/CT | Dr. Dana Clement
18:20 – 18:40 In favour ccRT +CT | Dr. Claudiu Hopirtean
18:40 – 18:50 Voting/Discussion
18:50 – 19:20 MTB – Case presentations | Dr. Dana Clement (15 min), Dr. Vladimir Preoteasa (15 min)
19:20 – 19:40 EGFR mutant: beyond first line Osimertinib based approach | Prof. Dr. Laura Mazilu
19:40 – 20:00 LD-SCLC – How to integrate ICI in the treatment algorithm of LD-SCLC | Prof. Dr. Tudor Ciuleanu
Multimodal Management of Gastric and Esophageal Cancer
14:00 – 14:20 Endoscopic and surgical approaches (EMR, ESD, neoadjuvant strategies) | Prof. Dr. Silviu Constantinoiu
14:20 – 14:40 Role of precision oncology: HER2, PD-L1, MSI | Șef Lucr. Dr. Luiza Șerbănescu
14:40 – 15:00 Radiotherapy in Esophageal Cancer: updates and perspectives | Șef Lucr. Dr. Toma Radu Valeriu
Hepato-bilio-pancreatic Cancers
15:00 – 15:30 Precision oncology: colangiocarcinoma, HCC, pancreatic cancer | Prof. Dr. Gerald Prager
15:30 – 16:00 Local therapies: nuclear medicine, HCC, colangiocarcinoma | Prof. Dr. Mirela Gherghe
Satellite Symposium
16:00 – 16:20 Satellite Symposium Servier – New Perspectives in First-Line Treatment of Metastatic Pancreatic Adenocarcinoma | Conf. Dr. Laurenția Galeș, Dr. Eniko Fejer
16:20 – 16:35 Satellite Symposium Servier – From Evidence-Based Choice to the Standard of Care in Third-Line Treatment for Patients with Metastatic Colorectal Cancer | Dr. Raluca Mihăilă
16:35 – 16:55 Satellite Symposium AstraZeneca – Himalaya Study: Aim for more Life in uHCC with STRIDE regimen | Dr. Andreea Lăzescu
16:55 – 17:20 Coffee Break
17:20 – 17:35 Satellite Symposium Accord Healthcare – RANKL inhibition with denosumab in breast cancer: implications for skeletal morbidity and disease outcomes | Dr. Mircea Dediu
Colorectal cancer
Molecular Pathways and Personalized Treatment Approaches
17:35 – 17:55 MSI-H, KRAS, NRAS, BRAF, HER2, NTRK: treatment implications | As. Univ. Dr. Iuliana Pantelimon
17:55 – 18:15 ctDNA and minimal residual disease monitoring, ctDNA for adjuvant therapies (de-escalation/escalation) | Conf. Dr. Oana Trifănescu
Beyond systemic therapy
18:15 – 18:35 Liver metastatectomy — when, for whom? | As. Univ. Dr. Șerban Marinescu
18:35 – 18:55 Ablative therapies: RFA/MWA, SBRT | Prof. Dr. Laurențiu Simion
18:55 – 19:15 Management of lung metastases | Dr. Bogdan Tănase
19:15 – 19:35 Rectal cancer: TNT, When we can skip surgery | Prof. Dr. Laura Rebegea